NCT04242199 : A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Female reproductive organs,Head and neck,Lung,Skin,Stomach and upper gastrointestinal tract,Urinary systemCervix,Cutaneous Squamous Cell Carcinoma (CSCC),Liver,Lung,Merkel cell,Mesothelioma,Nose (nasopharynx),Oesophagus,Small Cell Lung Cancer,Squamous cell carcinoma ,Urothelial

Trial Overview Read MoreRead more

This phase I trial is evaluating a new oral cancer drug in patients with select advanced solid cancers.
 

This trial is treating patients with select advanced cancers, including Cutaneous Squamous Cell Carcinoma, Urothelial Cancer, Cervical Cancer, Hepatocellular (Liver) Cancer, Oesophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma and Nasopharyngeal (Nose) Carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors

Commercial Sponsor

Incyte Corporation

Summary

Eligible patients will be assigned to a treatment cohort, depending on their tumour type and treatment history. All enrolled patients will receive either 25mg or 100mg oral INCB099280, once daily or twice daily, on each day of each 28-day cycle.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next